Spectranetics Acquires Covidien's Drug-Coated Angioplasty Balloon Platform for $30 million
Spectranetics announced that it acquired Covidien's drug-coated balloon platform, Stellarex, for $30 million.
Spectranetics announced on Nov. 2, 2014 that it reached an agreement to acquire Covidien’s drug-coated angioplasty balloon (DCB) platform, Stellarex, for $30 million. Spectranetics develops, manufactures, markets, and distributes single-use medical devices. Spectranetics would be able to advance the progress the Stellarex team has made during development, said Brian Verrier, president, Peripheral Vascular, Covidien in a press release.
The Stellarex DCB platform is designed to treat peripheral arterial disease with a uniform coating designed to prevent drug loss during transit and facilitate controlled drug delivery to the treatment site. The illuminate first-in-human study included 58 superficial femoral and/or popliteal lesions in 50 patients who were pre-dilated with an uncoated angioplasty balloon, followed by treatment with the Stellarex DCB. Studies found durable results for 24 months in 44 patients.
There are an additional four clinical trials ongoing in the US and internationally to evaluate drug levels in the blood, support PMA in the US, and test groups in a randomized and a non-randomized global trial. Currently, Stellarex DCB is not approved in any market; however, it is anticipated that it will receive European CE mark approval in late 2014 or early 2015.
Source: Covidien
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
